BrainStorm Cell Therapeutics to Provide Update on NurOwn Program

Core Viewpoint - BrainStorm Cell Therapeutics Inc. is set to provide an update on its NurOwn® program during a conference call scheduled for April 9, 2024, at 8:00 AM Eastern Time, aimed at informing shareholders and the investment community about recent developments [1]. Group 1: Company Overview - BrainStorm Cell Therapeutics Inc. specializes in developing innovative autologous adult stem cell therapies for neurodegenerative diseases [2]. - The company holds exclusive rights to the NurOwn® technology platform, which produces autologous MSC-NTF cells, and has received Orphan Drug designation from both the U.S. FDA and the European Medicines Agency for treating amyotrophic lateral sclerosis (ALS) [2]. - BrainStorm has completed a Phase 3 pivotal trial for ALS, which investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells, supported by a grant from the California Institute for Regenerative Medicine [2]. Group 2: Upcoming Events - The conference call will feature presentations from key executives, including the President and CEO, Co-CEO, and Chief Development Officer, followed by a Q&A session with the investment community [1]. - Participants can join the call via a provided link or by dialing specific toll-free and international numbers [1]. Group 3: Additional Information - A replay of the conference call will be available until April 24, 2024, allowing interested parties to listen to the discussion at a later time [1][2].